Core Viewpoint - The Board of Directors of Oma Savings Bank Plc has announced a new share-based incentive plan for key employees for the performance period of 2026–2028, transitioning from a two-year to a three-year program structure to better align employee interests with long-term company value [1][2]. Group 1: Incentive Plan Structure - The new incentive plan will consist of three-year performance periods starting annually, replacing the previous two-year programs [1]. - The plan aims to align the interests of shareholders and key employees, committing them to the company's long-term strategy and objectives [2]. Group 2: Target Group and Performance Criteria - Approximately 45 key employees, including the CEO and Management Team members, will be part of the 2026–2028 performance period [3]. - Performance rewards will be based on metrics such as return on equity, cost/income ratio, customer and employee satisfaction, and credit portfolio quality [3]. Group 3: Reward Structure - Rewards will be distributed partly in shares and partly in cash, with the cash portion intended to cover taxes and social security contributions [4]. - The total potential rewards correspond to approximately 330,000 shares, including cash components [4]. Group 4: Payment and Retention - Rewards will be deferred and paid in five installments over approximately four years post-performance period, followed by a one-year retention period for shares [5]. - Key executives must retain at least 50% of net shares until their shareholding value equals their gross annual salary [6]. Group 5: Performance Bonus Model - An annual performance bonus model will be expanded to include participants in the share-based incentive plan for 2026 and 2027, aligning with short-term performance criteria [7]. - Bonuses may be partially paid in shares if they exceed regulatory thresholds, with a total value corresponding to approximately 184,000 shares based on a share price of EUR 12.59 for February 2026 [10].

Core Insights - Can-Fite BioPharma Ltd. has made significant clinical advancements and reported financial results for the year ended December 31, 2025, highlighting progress in its drug development pipeline targeting oncological and inflammatory diseases [1] Clinical Updates - The Phase 2a study in pancreatic cancer met its primary safety endpoint, with over 30% of patients alive at the last data cut-off [2] - A patient with advanced hepatocellular carcinoma (HCC) treated with Namodenoson has achieved over 9 years of overall survival and remains cancer-free, supporting its potential as a novel therapeutic option [3] - Complete resolution of esophageal varices was observed in a patient with decompensated liver cirrhosis, indicating Namodenoson's potential as a disease-modifying therapy [4] - Namodenoson has expanded its therapeutic potential into metabolic diseases, including obesity, supported by new scientific findings and patent allowances [5] - The company has strengthened its intellectual property portfolio with multiple patent allowances across key territories, enhancing its long-term commercial positioning [6] Financial Results - Revenues for the year ended December 31, 2025, were $0.41 million, a decrease of 40% from $0.67 million in 2024, primarily due to lower advance payments from distribution agreements [8] - Research and development expenses increased by 16.26% to $6.69 million, driven by ongoing studies for Namodenoson and Piclidenoson [9][10] - General and administrative expenses rose by 20.2% to $3.66 million, mainly due to increased investor relationship expenses [11] - The net loss for the year was $9.83 million, compared to a net loss of $7.88 million in 2024, attributed to higher research and development and administrative expenses [13] - As of December 31, 2025, cash and cash equivalents totaled $8.54 million, an increase from $7.88 million in 2024, mainly due to higher net cash from financing activities [14] Company Overview - Can-Fite BioPharma Ltd. is focused on developing drugs for multi-billion dollar markets in cancer, liver, and inflammatory diseases, with its lead drug candidate, Piclidenoson, recently reporting positive results in a Phase III trial for psoriasis [21][28]

Core Insights - Polyrizon Ltd. has concluded 2025 with a strong cash position of approximately $17.5 million and a debt-free balance sheet, enabling significant advancements in its innovative nasal programs [2][5] - The company has made key regulatory progress with the FDA, including a productive Pre-Submission Meeting for its allergy blocker NASARIX™ and submitted a Pre-Request for Designation for its viral blocker [5] - Polyrizon is exploring potential revenue-generating investment opportunities in high-growth sectors such as private aviation and advanced eVTOL drone technologies, while maintaining financial flexibility [2] Company Achievements - The branding process for the allergy blocker NASARIX™ has been completed [2] - Positive preclinical data has been reported across multiple programs, including enhanced nasal deposition and mucoadhesion for the intranasal Naloxone Hydrogel program [5] - The company has signed an agreement with a leading global Preclinical CRO to support its clinical development pathway, with studies expected to commence in Q2 2026 [5] Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [3] - The proprietary Capture and Contain™ hydrogel technology functions as a "biological mask" and is being further developed for drug delivery [3] - An additional technology, Trap and Target™, is focused on the nasal delivery of active pharmaceutical ingredients and is in earlier stages of pre-clinical development [3]

Core Insights - No Frills® has opened its first store in Komoka, Ontario, at 370 Crestview Drive, continuing its commitment to providing everyday low prices to customers [1][3] - The new store features a hybrid timber and steel design, creating a modern and inviting atmosphere while maintaining the brand's value proposition [2][3] - The store offers a wide range of grocery essentials, including an expanded bakery section, Home Meal Replacement department, and multicultural products tailored to local community needs [3] Company Overview - Loblaw Companies Limited is Canada's largest food and pharmacy retailer, operating over 2,800 locations and employing more than 220,000 individuals [6][7] - The company aims to meet the diverse needs of Canadians through various services, including grocery, pharmacy, healthcare, and financial services [6][7] - Loblaw's purpose is to prioritize the well-being of Canadians, facilitating approximately one billion transactions annually across its stores [7] Community Engagement - The store's owners, Mike and Grace, expressed their excitement about contributing to the local community and announced a donation to local organizations addressing food insecurity [4] - The grand opening celebration reflects the company's ongoing commitment to community support and engagement [4] Store Operations - Mike and Grace's No Frills in Komoka operates daily from 7:00 a.m. to 9:00 p.m., providing convenient access to customers [5]

Core Insights - Global Technologies, LTD has successfully completed a comprehensive two-year independent audit and filed its recent quarterly reports under PCAOB supervision, including the restatement of its 2024 financial statements [1][3] - The company is now current in its financial reporting obligations with the SEC, having completed all required periodic reports through the quarter ended December 31, 2025 [2] - The audit was undertaken to enhance the reliability and transparency of financial disclosures, exceeding minimum regulatory requirements to strengthen internal controls and investor confidence [3][4] Company Strategy and Future Outlook - The CEO emphasized the importance of transparency and accountability, stating that the company aims to provide clear disclosures to stakeholders [5] - With its reporting status current and enhanced financial oversight, the company believes it is well-positioned for improved market visibility and future growth opportunities [5] - Global Technologies plans to provide updates on key operating metrics, including sales velocity, client growth, and revenue expansion across its core subsidiaries as part of its growth strategy [5] Company Overview - Global Technologies, LTD is a public, multi-operational company focused on scalable businesses in digital health, wellness, and technology, aiming to deliver innovative solutions and long-term shareholder value through acquisitions and strategic licensing [6]

Core Viewpoint - Edesa Biotech, Inc. is advancing its Phase 2 clinical study of EB06 for moderate-to-severe nonsegmental vitiligo, with enrollment expected to begin mid-2026, following the selection of JSS Medical Research as its clinical research organization [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immuno-inflammatory diseases, with a pipeline that includes EB06 for vitiligo and other assets for allergic contact dermatitis and respiratory conditions [7][8] Clinical Study Details - The Phase 2 study will assess the safety and efficacy of EB06 compared to placebo in adults with non-segmental vitiligo, involving intravenous infusions during the treatment period followed by a follow-up [4] - Site activations and patient recruitment for the clinical trial are anticipated to start in mid-2026, with initial sites located in Canada [2] Drug Mechanism and Background - EB06 is a monoclonal antibody targeting chemokine ligand 10 (CXCL10), which is implicated in the autoimmune response in vitiligo by promoting the trafficking of anti-melanocytic T-cells and inducing melanocyte apoptosis [5][6] - Preclinical studies have shown that EB06 can prevent and reverse depigmentation, demonstrating pharmacodynamic activity necessary to address the immune dysfunction associated with vitiligo [5] Vitiligo Overview - Vitiligo is a chronic autoimmune condition affecting 0.5% to 2% of the global population, characterized by unpredictable loss of skin pigmentation, often beginning before the age of 20 [6]

Core Insights - Draganfly Inc. is positioned as a leader in drone technology and unmanned aerial vehicle (UAV) solutions, highlighting operational progress and a strong balance sheet amidst market volatility [1][2] Financial Strength - The company has approximately $145 million in cash, providing significant financial flexibility for growth initiatives, with its market valuation modestly above its cash position [2] Global Defense and Tier-One Momentum - Draganfly is expanding its presence in the Global Defense ecosystem, reinforcing its status as a trusted North American provider of compliant unmanned systems [3] Favorable Industry Dynamics - There is an accelerating global demand for drone and autonomous systems, driven by various factors, indicating a sustained structural shift that supports long-term growth [4] 2026 Priorities - The company is focused on several key initiatives, including scaling production and delivery capabilities, developing domestic supply chains, and expanding government and Tier-one contractor relationships [7] Recent Achievements - Draganfly has been selected to supply Flex FPV systems to the U.S. Air Force Special Operations Command and is participating in the Secretary of War's Drone Dominance Program Phase 1 [6] - The company achieved a perfect score in the "Urban Strike" mission and is deploying the Commander 3XL platform in extreme environments [6] Industry Trends - There is a rapid adoption of FPV and ISR technologies in modern conflict, increased defense spending on autonomous capabilities, and heightened security demand in regions like the Middle East [7]

Core Viewpoint - Nasdaq has approved the ticker symbol "TEMB" for Tembo Group, marking a significant regulatory milestone for the business combination between VivoPower's subsidiary Tembo e-LV and Cactus Acquisition Corporation I [1][2] Company Overview - VivoPower is a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, with a mission to support sovereign nations in developing sustainable data center infrastructure [10] - Tembo specializes in electric utility vehicles (EUVs) designed for rugged and customized applications across various industries, including mining, agriculture, and defense [7] Business Combination Details - The business combination values Tembo at a pre-money indicative equity value of approximately US$838 million [3] - VivoPower expects to retain a significant equity interest in Tembo Group following the completion of the business combination [3][5] - The transaction is subject to final closing conditions, including SEC registration and shareholder approvals [4][9] Strategic Investment - Tembo has secured long-term strategic investment capital from the Emirates, eliminating the need for structured PIPE capital [5]

Core Insights - Royal Philips has received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution designed to assist physicians in minimally invasive mitral valve repair procedures [2][15] Group 1: Product Development and Collaboration - DeviceGuide was developed in collaboration with Edwards Lifesciences, combining Philips' imaging and AI expertise with Edwards' knowledge in valvular heart therapy [3] - The software integrates Philips' EchoNavigator technology, which fuses live echocardiography and X-ray images, providing real-time AI guidance during procedures [6][9] - Clinical partners, including NewYork-Presbyterian/Columbia University, contributed to the development of DeviceGuide, enhancing its practical application in real-world settings [10] Group 2: Market Impact and Patient Care - Mitral regurgitation (MR) affects over 35 million adults globally, with more than 2 million cases in the U.S., highlighting the significant market potential for DeviceGuide [4] - DeviceGuide aims to streamline the complex M-TEER procedures, improving accuracy and coordination among medical teams, ultimately enhancing patient outcomes [12][14] - The technology is part of Philips' broader connected cardiology ecosystem, which aims to improve procedural efficiency and support patient recovery [13][14] Group 3: Future Outlook and Availability - DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting, indicating its relevance in the field of cardiovascular innovation [4] - The product is currently intended for use with the Edwards PASCAL Ace Mitral Valve Repair System, with commercial availability subject to regulatory requirements [15]

Core Viewpoint - Cerro de Pasco Resources Inc. has entered into an access and investigation agreement with Activos Mineros S.A.C., allowing surface access to the Quiulacocha Tailings Storage Facility, marking a significant milestone in the development of the Quiulacocha Tailings Reprocessing Project [1][2][3] Group 1: Agreement Details - The agreement provides CDPR with surface access, operational coordination, and drilling activities across the entire tailings area, complementing existing concession rights [4][6] - The total consideration for the agreement is approximately PEN 7.2 million (around US$ 2.1 million), structured to facilitate access to the Quiulacocha Project area [11] - The agreement allows for flexibility in extension, supporting ongoing project development activities as the company progresses through technical and permitting milestones [12] Group 2: Project Advancement - The collaboration with AMSAC represents a strategic shift, enabling a comprehensive development approach and a more direct path for project advancement [3][7] - CDPR plans to commence drilling activities in mid-2026, pending standard permitting and operational planning [5] - The agreement establishes a framework for advancing key milestones, including drilling, resource definition, feasibility studies, and environmental permitting [10][13] Group 3: Management Commentary - The CEO of Cerro de Pasco Resources emphasized that this agreement is a major milestone for the Quiulacocha Project, which shareholders have been anticipating [8] - The company views this agreement as essential for unlocking the full potential of the Quiulacocha Project and generating the necessary technical data for long-term development [14]